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Sphingosine 1-Phosphate Restrains Insulin-Mediated
Keratinocyte Proliferation via Inhibition of Akt
through the S1P2 Receptor Subtype
Melanie Schu¨ppel1, Ulrich Ku¨rschner1, Ulrike Kleuser1, Monika Scha¨fer-Korting1 and Burkhard Kleuser1
The balance between keratinocyte proliferation and differentiation plays a decisive role for skin formation and
development. Among the well-characterized biological mediators, insulin and sphingosine 1-phosphate (S1P)
have been identified as major regulators of keratinocyte growth and differentiation. Insulin induces
proliferation of keratinocytes, whereas S1P inhibits keratinocyte growth and initiates keratinocyte differentia-
tion. However, it is not clear which S1P receptor subtype and downstream signaling pathways are involved in
the antiproliferative action of S1P. In this study, we present evidence that S1P inhibits insulin-mediated
keratinocyte growth via the activation of protein kinase C (PKC) followed by a subsequent dephosphorylation
of Akt. The inhibition of insulin-mediated Akt activity by S1P is completely abolished in the presence of PKCd
siRNA indicating that this isozyme is selectively potent at causing dephosphorylation of Akt and modifying
keratinocyte proliferation. Further experiments by downregulation of S1P receptor subtypes and the use of
specific receptor agonists/antagonists clearly indicated that the S1P2 receptor is dominantly involved in the
S1P-induced dephosphorylation of Akt and keratinocyte growth arrest. This is of great clinical interest, as the
immunomodulator FTY720, after being phosphorylated by sphingosine kinase, activates all of the five S1P
receptors except S1P2 and therefore fails to inhibit keratinocyte proliferation.
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INTRODUCTION
The equilibrium between cell growth and cell differentiation
plays a pivotal role in many physiological processes. In skin,
the maintenance of the balance between proliferation of
mitotically active epidermal keratinocytes and differentiation
of postmitotic skin cells is particularly critical for skin
formation and development (Koria and Andreadis, 2006).
Indeed, under certain pathological conditions, the interplay
between proliferation and differentiation can be disturbed,
which may result in an impaired wound healing, hyper-
proliferative skin diseases, or even tumorigenesis (Fuchs and
Raghavan, 2002). Thus, it is not astonishing that keratinocyte
proliferation and differentiation are controlled by a complex
network of several growth factors and cytokines.
Among the well-characterized growth factors, insulin and
IGF-I have been identified as critical regulators of cellular
proliferation and differentiation (Wertheimer et al., 2000;
Sadagurski et al., 2006). Both mediators bind to specific
receptors belonging to the tyrosine kinase family of growth
factor receptors (Cheatham and Kahn, 1995; LeRoith et al.,
1995; Dupont and LeRoith, 2001). Receptor expression
studies have demonstrated the presence of the insulin receptor
(IR) and the IGF-I receptor (IGF-IR) in dermal and epidermal
cells, suggesting their function in skin development (Verrando
and Ortonne, 1985; Misra et al., 1986; Goren et al., 2006).
Indeed, increasing IR/IGF-IR signaling is associated with
enhanced cell proliferation, skin hyperplasia, and tumori-
genesis (Giovannucci, 1999; DiGiovanni et al., 2000; Shen
et al., 2001). In conclusion, mice with disrupted IGF-IR are
characterized by a thinner and defective epidermis (Martin,
1997). It has been well established that insulin induces
proliferation not only via the ligation to IR but also to IGF-IR
(Kuhn et al., 1999; Edmondson et al., 2003). In response to IR
and IGF-IR stimulation, the signal is propagated via at least
two main signaling pathways, the Ras/Raf/mitogen-activated
protein kinase pathway and the phosphoinositide-3 kinase/Akt
pathway, respectively (Kooijman, 2006).
Especially in keratinocytes, the phosphoinositide-3 kinase/
Akt signaling pathway is of great importance in regulation of
cell proliferation (Murayama et al., 2007; Ouyang et al.,
2007). The serine/threonine kinase Akt has been identified as
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a key downstream target of phosphoinositide-3 kinase in
insulin-regulated processes leading to the formation of
phosphatidylinositol-3,4,5-trisphosphate and subsequent
phosphorylation of Akt by the phosphoinositide-dependent
kinase-1 at the two regulatory phosphorylation sites Thr308
and Ser473 (Kandel and Hay, 1999; Lawlor and Alessi, 2001;
Scheid and Woodgett, 2003; Song et al., 2005). In keratino-
cytes, these phosphorylations result in cell cycle progression
via regulation of D-type cyclins and cyclin-dependent kinase
inhibitors, p21WAF1/CIP1 (p21) and p27KIP1 (p27) (Blagosklon-
ny, 2002; Liang et al., 2002; Shin et al., 2002). Thus, it is not
astonishing that activation of Akt is enhanced in hyperproli-
ferative states and malignant transformation of keratinocytes
(Wilker et al., 2005; Pankow et al., 2006; Segrelles et al.,
2006).
In addition, the protein kinase C (PKC) family of serine/
threonine kinases was identified as a critical regulator of
keratinocyte proliferation and differentiation (Matsui et al.,
1992; Gartsbein et al., 2006). Among the 12 members of the
PKC family, PKCa, PKCd, PKCe, PKCZ, PKCz, and PKCm have
been localized in the epidermis (Dlugosz et al., 1992, 1994;
Gschwendt et al., 1996). Skin targeting of PKC isozymes in
transgenic mice has indicated that overexpression of PKCd
and PKCe is connected with a reduction in the number of
benign tumors induced by chemical carcinogenesis (Newton,
2003). Moreover, it has been shown that PKCd and PKCe are
selectively potent at causing dephosphorylation of Akt, which
may explain their tumor-inhibiting action (Li et al., 2006).
Sphingolipids have long been recognized as important
structural components of the epidermis, securing its perme-
ability barrier. Moreover, recent findings suggest a substantial
role of the sphingolipid sphingosine 1-phosphate (S1P) as a
bioactive mediator involved in the regulation of keratinocyte
growth and differentiation (Vogler et al., 2003; Kim et al.,
2004; Sauer et al., 2004). Although S1P is a potent mitogen in
a variety of cells, an opposed effect is visible in human
keratinocytes, as S1P inhibits cell growth of epidermal cells
(Manggau et al., 2001; Vogler et al., 2003; Radeff-Huang
et al., 2004).
S1P has been suggested to exert most of its actions as a
ligand for G-protein-coupled receptors (Spiegel and Milstien,
2003; Ishii et al., 2004; Chalfant and Spiegel, 2005; Hait
et al., 2006). To date, five members of the S1P receptor family
have been identified, namely S1P1–5, which are all expressed
in human keratinocytes (Vogler et al., 2003). The first
available drug acting on S1P receptors is FTY720 (2-amino-
2-(2-[4-octylphenyl]ethyl)-1,3-propanediol), which is pre-
sently in clinical development for suppression of transplant
rejection and multiple sclerosis. FTY720, after being phos-
phorylated by sphingosine kinase, activates all of the five S1P
receptors except S1P2 (Brinkmann et al., 2004).
In this report, we identified an interplay between insulin
and S1P, but not FTY720, on Akt signaling, PKC activity,
and keratinocyte cell growth. Most interestingly, these
S1P-mediated actions are transduced via the receptor
subtype S1P2. Therefore, true agonists on the S1P2 may be
of great interest in the treatment of hyperproliferative skin
diseases.
RESULTS
S1P inhibits insulin-dependent Akt phosphorylation and
keratinocyte growth
Several studies indicate that insulin induces proliferation of
human keratinocytes, whereas S1P mediates keratinocyte cell
growth arrest (Shen et al., 2001; Vogler et al., 2003). As Akt
has been identified as an important regulator of cell
proliferation, we have further evaluated the interplay of both
mediators on Akt phosphorylation (Ouyang et al., 2007).
Therefore, primary human keratinocytes were grown under
serum-free conditions and then stimulated with either S1P or
insulin, or both stimulants. As indicated in Figure 1a, S1P
significantly reduced phosphorylation of constitutively active
Akt in cultured basal keratinocytes in a transient manner,
whereas the levels of total Akt were not affected. A time-
course study indicated that the dephosphorylation of Akt on
Ser473 was first visible after 10minutes and persisted over a
time period of 1 hour. In contrast to S1P, insulin induced a
substantial phosphorylation of Akt on Ser473. A maximal
effect was detected after 10minutes with 1 mM of insulin
(Figure 1b). Most interestingly, pretreatment of keratinocytes
with S1P reduced the ability of insulin to induce Akt
phosphorylation. Figure 1c indicates that S1P-induced
inhibition of insulin-dependent Akt activation was dose-
dependent. Thus, S1P (10 mM) completely abolished insulin-
mediated Akt activation. It should be mentioned that the
capability of insulin to mediate Akt phosphorylation was
significantly reduced when keratinocytes were pretreated
with S1P over a time period of 10minutes. To investigate the
biological consequences of the S1P/insulin interplay on the
Akt-mediated cell growth pathway, proliferation experiments
were performed. As expected, insulin induced a strong
mitogenic effect of quiescent primary human keratinocytes
(Figure 2a). But when cells were pretreated with S1P, insulin
failed to evoke its mitogenic signaling. As shown in Figure 2b,
S1P inhibited insulin-mediated proliferation in a dose-
dependent manner. When human keratinocytes were pre-
treated with 10 mM of S1P, the insulin-dependent increase of
proliferation was almost completely annihilated, which is in
agreement with the inhibitory effect of S1P at this concentra-
tion on Akt phosphorylation.
S1P induces Akt dephosphorylation via activation of PKCd
It has been indicated that activation of PKC is a negative
modulator of Akt phosphorylation in primary mouse kerati-
nocytes (Li et al., 2006). Therefore, it was of interest to prove
whether S1P is able to activate PKC in primary human
keratinocytes and whether this effect contributes to the
S1P-mediated inhibition of Akt activation. To this end,
phosphorylation of the C-terminal residue in the hydrophobic
motif of PKC isozymes, homologous to Ser660 of PKCbII, was
measured. S1P at several concentrations was added to
quiescent keratinocytes for several incubation periods, and
cell lysates were analyzed for PKC activation. Indeed, S1P
induced phosphorylation of PKC. As presented in Figure 3a,
the time course of activation of PKC was rapid and similar to
the time course of the S1P-mediated inhibitory effect on Akt
activation. A maximal response on PKC activity occurred
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after 5minutes of S1P treatment and returned to basal levels
after 60minutes (Figure 3a). The most effective dose to
stimulate PKC activity was 10 mM of S1P, which is similar to
the concentration inhibiting Akt phosphorylation (data not
shown). To further support the fact that PKC activation leads
to a dephosphorylation of Akt in human keratinocytes, the
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Figure 1. S1P inhibits basal and insulin-induced Akt phosphorylation. Human keratinocytes were treated with (a) 10 mM S1P or (b) 1 mM insulin for the indicated
time periods followed by the detection of Akt activity using western blot analysis. (c) Cells were pretreated with the indicated S1P concentrations for 10minutes
followed by stimulation with 1 mM insulin for another 10minutes. Values of the densitometric analysis are expressed as x-fold increase of phospho-Akt formation
(a and b) compared to untreated cells±SED or (c) compared to insulin-treated cells±SED from three experiments. *Po0.05 and **Po0.001 indicate a
statistically significant difference (a and b) versus unstimulated control cells and (c) versus insulin-treated cells.
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Figure 2. S1P inhibits insulin-induced proliferation. Keratinocytes were
(a) incubated with the indicated concentrations of insulin or (b) pretreated for
10minutes with the indicated concentrations of S1P followed by a subsequent
stimulation with 1 mM insulin. After 24 hours, [3H]thymidine incorporation
was measured. Values are expressed as x-fold increase compared to control
and are the mean±SED from three experiments. *Po0.05 and **Po0.001
indicate a statistically significant difference (a) versus unstimulated control
cells and (b) versus insulin-treated cells.
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Figure 3. Stimulation of PKC by S1P impairs Akt activity and proliferation.
(a) Human keratinocytes were treated with 10 mM S1P for various time periods
followed by the detection of basal and phosphorylated PKC levels using
western blot analysis. (b) Cells were preincubated with 250 nM TPA or vehicle
for 15minutes followed by stimulation with 1 mM insulin for 10minutes, and
Akt activity was detected by western blot analysis. (c) Keratinocytes were
pretreated with either 10 mM S1P for 10minutes or 250 nM TPA for 15minutes
followed by incubation with 1mM insulin. After 24 hours, cells were pulsed
with [3H]thymidine. Values are expressed as x-fold increase compared to
control and are the mean±SED from three experiments. **Po0.001 indicates
a statistically significant difference (a) versus unstimulated control cells and
(b and c) versus insulin-treated cells.
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direct PKC activator 12-O-tetradecanoylphorbol-13-acetate
(TPA) was used. In analogy to S1P, TPA caused depho-
sphorylation of basal Akt activity and significantly abrogated
the insulin-dependent phosphorylation of Akt on Ser473 in
human keratinocytes (Figure 3b). In accordance, measure-
ment of proliferation indicated that pretreatment of keratino-
cytes with TPA inhibited the insulin-mediated increase of
keratinocyte cell growth (Figure 3c). As previous studies
indicated the involvement of especially PKCd on Akt depho-
sphorylation, the ability of S1P to stimulate this PKC isozyme
was examined (Li et al., 2006). As presented in Figure 4a, S1P
strongly activated PKCd in a time-dependent manner. The
most effective concentration of S1P to phosphorylate PKCd
was 10 mM (data not shown). To further substantiate the role of
PKCd in S1P-induced Akt modulation, on the one hand, the
selective inhibitor rottlerin was used and, on the other hand,
PKCd was downregulated by small interfering RNA (siRNA).
Treatment of siRNA-transfected cells with TPA confirmed the
effective downregulation of PKCd (Figure 4c, upper panel).
Indeed, S1P did not reduce insulin-induced Akt phosphoryla-
tion when PKCd was abrogated by siRNA technology (Figure
4b). These findings were confirmed by the use of rottlerin, as
it also prevented the effect of S1P on Akt modulation (data not
shown). Finally, proliferation was measured in PKCd-down-
regulated cells. According to the Akt phosphorylation status,
S1P lost its ability to inhibit insulin-induced proliferation
(Figure 4c).
S1P mediates its action on Akt, PKCd, and proliferation via the
S1P2 receptor subtype
Next, it was of interest to evaluate whether Akt depho-
sphorylation induced by S1P is a receptor-mediated process.
Recently, we have indicated that human keratinocytes
express mRNA transcripts of all five S1P receptors (Vogler
et al., 2003). On the basis of these studies, we performed real-
time PCR to quantify mRNA of S1P receptors in primary
human keratinocytes. The relative amount of S1P receptor
mRNA was S1P54S1P14S1P44S1P24S1P3 (Figure 5a).
Employing antisense technique, we further sought to eluci-
date which receptor subtype is responsible for the inhibition
of Akt activation. Real-time PCR analysis revealed that
treatment of cells with S1P1, S1P2, S1P3, S1P4, and S1P5
antisense phosphorothioate oligonucleotides (ASOs) resulted
in a serious reduction of mRNA levels (Figure 5b). As
presented in Figure 6, abrogation of the receptor subtypes
S1P1, S1P3, S1P4, and S1P5 did not abolish the S1P-induced
Akt dephosphorylation. Most interestingly, only abrogation of
the S1P2 receptor subtype influenced the ability of S1P to
modulate Akt phosphorylation. Thus, downregulation of the
S1P2 prevents the inhibitory effect of S1P on insulin-mediated
6
5
4
3
2
1
0
6
5
4
3
2
1
0
0
1
2
Th
ym
id
in
e 
in
co
rp
or
a
tio
n 
(%
 of
 co
ntr
ol)
3
siR
NA
 PK
Cδ
/ins
ulin
siR
NA
 PK
Cδ
/ins
ulin
/S1
P
Co
ntr
ol s
iRN
A/i
nsu
lin
Co
ntr
ol s
iRN
A/i
nsu
lin/
S1
P
siR
NA
 PK
Cδ
/ins
ulin
TP
A/P
KC
δ s
iRN
A
TP
A/c
ont
rol 
siR
NA
Co
ntr
ol
siR
NA
 PK
Cδ
/ins
ulin
/S1
P
Co
ntr
ol s
iRN
A/i
nsu
lin
Co
ntr
ol s
iRN
A/i
nsu
lin/
S1
P
Ins
ulin
/S1
P
Ins
ulin
Co
ntr
ol
S1P (minutes)C
on
tro
l
TP
A 60 30 10 5
∗∗ ∗∗
∗∗
∗∗
∗
R
at
io
 P
-P
KC
δ/
PK
Cδ
P-PKCδ
P-PKCδ
PKCδ siRNA
Control siRNA
PKCδ
R
at
io
 P
-A
kt
/A
kt
P-Akt
Akt
S1P (minutes)C
on
tro
l
TP
A 60 30 10 5
Figure 4. PKCd activation by S1P inhibits keratinocyte proliferation via Akt dephosphorylation. (a) Cells were treated with 10 mM S1P for the indicated
time periods or with 250 nM TPA for 15minutes, and PKCd activation was measured by western blot analysis. (b) Keratinocytes were transfected with siRNA
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Akt activation, indicating that this receptor subtype is
responsible for the interplay between S1P and insulin
signaling (Figure 7a). To further substantiate the involvement
of S1P2, actions of S1P were examined in the presence of
JTE013, a well-established antagonist of this receptor subtype.
In accordance to the findings using ASO technique against
S1P2, S1P completely lost its ability to impair insulin-induced
Akt phosphorylation in the presence of JTE013 (Figure 7b).
Additionally, we proved whether S1P2 receptor subtype is
also responsible for the activation of PKCd. As presented in
Figure 7c, abrogation of S1P2 almost completely diminished
the stimulatory effect of S1P on PKCd. To substantiate the role
of the S1P2 receptor subtype not only on PKCd activation and
Akt dephosphorylation but also on inhibition of insulin-
mediated proliferation, thymidine incorporation was per-
formed in the absence of S1P2. Actually, S1P did not
significantly reduce insulin-mediated proliferation in case of
S1P2 downregulation (Figure 7d).
The S1P analogue FTY720-phosphate does not inhibit insulin-
mediated Akt phosphorylation and proliferation
Next, it was of great interest to investigate the role of
FTY720-phosphate (FTY720-P; phosphoric acid mono[(R/S)-
2-amino-2-hydroxymethyl-4-(4-octylphenyl)butyl]ester) on
Akt modulation and keratinocyte proliferation, as this
immunomodulator acts on all S1P receptor subtypes except
S1P2. Consequently, FTY720-P neither influenced the basal
activity of Akt nor inhibited insulin-mediated Akt phosphory-
lation (Figure 8a). As we have identified Akt dephosphory-
lation as the essential pathway of S1P via S1P2 to inhibit
keratinocyte cell growth, we also investigated the influence
of FTY720-P on keratinocyte proliferation. As expected,
proliferation measurements revealed that FTY720-P, in
contrast to S1P, was not able to inhibit the insulin-mediated
cell growth (Figure 8b). Taken together, our results indicate
that S1P inhibits insulin-dependent cell growth of human
keratinocytes via the activation of PKC, followed by a
subsequent inhibition of Akt phosphorylation. S1P2 has been
identified as the crucial receptor subtype for this action. This
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is of importance, as the immunomodulator FTY720 is not a
true agonist at this receptor subtype and therefore fails to
suppress growth factor-mediated proliferation of human
keratinocytes.
DISCUSSION
Cross-talk of multiple signaling pathways activated by growth
factors and cytokines plays a pivotal role in the regulation of
proliferation and differentiation of many cell types. Most
interestingly, our study demonstrates a complex interplay of
the bioactive molecules insulin and S1P in human keratino-
cytes. Herein, we present evidence that activation of the S1P2
receptor subtype by its physiological ligand S1P inhibits
insulin-mediated cell growth of human keratinocytes via the
activation of PKCd followed by a subsequent dephosphoryla-
tion of Akt.
Several studies have pointed out a role for insulin and
IGF-I in the pathogenesis of psoriasis. Thus, keratinocytes
derived from psoriasis patients are more susceptible to
IGF-I-stimulated proliferation in vitro than keratinocytes from
non-affected individuals (Ristow, 1993). Moreover, the
IGF-IR is more abundant in psoriatic lesions (Hodak et al.,
1996). Therefore, it has been proposed that inhibition of
IR/IGF-IR signaling would be an effective way of treating
psoriatic epidermal hyperplasia. Indeed, antisense oligonu-
cleotides against IGF-IR caused a dramatic normalization of
the hyperplastic epidermis in mice, indicating that interfering
of IGF-I signaling forms the basis of a potential psoriasis
therapy (Wraight et al., 2000).
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Our data indicate that the sphingolipid metabolite S1P
interferes with IR/IGF-IR signaling, resulting in an almost
complete inhibition of insulin-mediated keratinocyte prolife-
ration. Although it is well known that S1P acts as a positive
regulator of cell growth in many cell types (Hla, 2003;
Spiegel and Milstien, 2003), an antiproliferative effect of the
sphingolipid has been previously reported in hepatic
myofibroblasts, rat hepatocytes, mouse myoblasts, and in
human keratinocytes (Davaille et al., 2000; Ikeda et al., 2003;
Kim et al., 2004; Donati et al., 2005).
Despite our increasing knowledge of S1P as cell growth
inhibitor, the involved signaling pathways in epidermal cells
have not been well characterized. It is well established that
Akt phosphorylation plays an important role in regulating cell
growth of a variety of cells. Overexpression of Akt has been
reported in a number of human cancers (Testa and Bellacosa,
2001; Itoh et al., 2002; Bellacosa et al., 2005). In addition, a
marked enhancement of Akt phosphorylation can also be
detected in psoriatic skin (Rosenberger et al., 2007). S1P
possesses a divergent role on Akt phosphorylation depending
on the cell type (Igarashi et al., 2001; Baudhuin et al., 2002;
Kim et al., 2003, 2004; Balthasar et al., 2006). In a variety of
cells, S1P is able to induce Akt phosphorylation, which is in
accordance to its positive role on proliferation in these cells
(Rosenberger et al., 2007). In keratinocytes, it has been
described that S1P inhibits cyclin D2 and induces p21 and
p27 (Kim et al., 2004). Thus, the cell cycle arrest correlates
with the S1P-induced inhibition of Akt activation.
This study has indicated that PKC activation reduces Akt
phosphorylation under both basal and insulin-stimulated
conditions. Moreover, S1P induces PKC phosphorylation,
and inhibition of PKC completely abolished S1P-induced Akt
dephosphorylation in human keratinocytes. Both positive and
negative regulation of Akt phosphorylation by PKC has been
reported previously, and it has been suggested that individual
PKC isozymes have specific functions in the regulation of Akt
phosphorylation (Thors et al., 2003; Li et al., 2006). Most
interestingly, a decreased PKC activity has been identified in
psoriatic epidermis, suggesting the important role of PKC
activity in the regulation of proliferation (Horn et al., 1987).
Using adenovirus-mediated overexpression of PKC isozymes
in keratinocytes, especially PKCd has been identified as the
crucial isozyme that determines the sensitivity of Akt to TPA-
induced dephosphorylation (Li et al., 2006). This is consistent
to our results, as the use of rottlerin and siRNA against PKCd
confirmed the essential role of this isozyme on the modula-
tion of proliferation and Akt activity. In accordance to the
present findings, PKCd activity induces differentiation and
inhibits proliferation in HaCaT cells (Papp et al., 2004). As we
clearly indicate that S1P stimulates PKCd, it is not astonishing
that this sphingolipid is also able to induce differentiation of
epidermal cells (Balasubramanian et al., 2006). But it should
be mentioned that the effect of PKCd overexpression on
keratinocyte cell growth has been controversially discussed
(Li et al., 1999; Denning et al., 2002; Gartsbein et al., 2006).
Although Shen et al. (2001) suggested that PKCd activation is
involved in insulin-mediated proliferation of mouse kerati-
nocytes, our results clearly indicate that in case of abrogation
of PKCd, S1P fails to inhibit insulin-induced Akt phosphory-
lation and proliferation.
To our knowledge, this study figures out a previously
unreported function of the S1P2 receptor subtype in human
keratinocytes. Abrogation of S1P2 restored not only the
inhibitory effect of S1P on Akt phosphorylation and
proliferation but also prevented the S1P-induced PKCd
activation. In congruence to our results, the antiproliferative
effect of S1P in rat hepatocytes and mouse myoblasts was
mediated by the same receptor subtype (Ikeda et al., 2003;
Donati et al., 2005). However, in disagreement, S1P2 was
found as the crucial receptor subtype to induce a mitogenic
signaling in mouse mesangial cells and in mouse hepatic
myofibroblasts (Katsuma et al., 2002; Serriere-Lanneau et al.,
2007). This apparent discrepancy can be explained taking
into account the high cellular specificity of the signaling
pathways initiated by individual S1P receptor subtypes.
In particular, our findings indicate that S1P2 activation is to
be considered a therapeutic target for hyperproliferative skin
diseases. Therefore, the development of S1P2 receptor
subtype-specific ligands might be highly important for such
medicinal interventions. It is of interest that the first available
drug acting on S1P receptors, the phosphorylated FTY720,
activates all of the five S1P receptors except S1P2 and
therefore fails to inhibit keratinocyte proliferation.
MATERIALS AND METHODS
Materials
S1P was purchased from Biomol (Hamburg, Germany). S1P was
dissolved in methanol and stored at 80 1C. For each experiment,
stored S1P was dried and freshly diluted in 0.4% fatty acid-free serum
albumin (BSA)/phosphate-buffered saline (PBS). FTY720 was
from Biozol Diagnostica (Eching, Germany). JTE013 was obtained
from Tocris (Ellisville, MO). TPA was purchased from Calbiochem/
Merck Biosciences (Darmstadt, Germany). Insulin, rottlerin, fatty
acid-free BSA, trypsin, PBS, Ipegal, sodium desoxycholate, SDS,
phenylmethylsulfonyl fluoride, leupeptin, aprotinin, pepstatin, EDTA,
sodium fluoride, sodium orthovanadate, DMSO, DMEM, and
penicillin/streptomycin were purchased from Sigma-Aldrich (Tauf-
kirchen, Germany). Fetal bovine serum and Optimem were obtained
from Biochrom (Berlin, Germany). Keratinocyte basal medium,
epidermal growth factor, insulin, hydrocortisone, bovine pituitary
extract, gentamycin sulfate, and amphotericin B were purchased from
Lonza (Verviers, Belgium). Polyclonal rabbit anti-phospho-Akt
(Ser473) antibody, polyclonal rabbit anti-phospho-PKC (pan) (bII
Ser660) antibody, polyclonal rabbit anti-phospho-PKCd (Thr505)
antibody, polyclonal rabbit anti-Akt-antibody, anti-rabbit IgG,
anti-mouse IgG, SDS sample buffer, dithiothreitol, LumiGlo reagent,
and peroxide were obtained from New England Biolabs (Beverly,
MA). Monoclonal mouse anti-PKC antibody, PKCd siRNA, control
siRNA, siRNA transfection reagent, and transfection medium were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Polyvinylidene difluoride membranes were obtained from Millipore
(Schwalbach, Germany). TransIT-LT1s transfection reagent was
purchased from KMF Laborchemie (Lohmar, Germany). Control
oligonucleotides, ASO, and primers were synthesized by TIB Molbiol
(Berlin, Germany). [methyl-3H]Thymidine (35CimM1) was pur-
chased from Amersham Pharmacia Biotech (Freiburg, Germany).
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Synthesis of FTY720-P
FTY720-P was synthesized from FTY720, as recently described (Albert
et al., 2005). Briefly, FTY720 was protected as an oxazolidinone by
the addition of benzyl chloroformate. Then, phosphorylation of the
free hydroxyl group was carried out by addition of 3-(diethylamino)-
1,5-dihydro-2,4,3-benzodioxaphosphepintriphenyl phosphite and a
subsequent oxidation to obtain (R/S)-4-[2-(4-octylphenyl)ethyl]-4-(3-
oxo-1,5-dihydro-3l5-benzo[e][1,3,2]dioxaphosphepin-3-yloxymethyl)
oxazolidin-2-one. The phosphate-protecting group was removed by
hydrogenation, and the oxazolidinone was cleaved with lithium
hydroxide yielding to FTY720-P. Identity was checked by electrospray
ionization time-of-flight (TOF) mass spectrometry using an Agilent
6210 TOF LC/MS (Agilent, Waldbronn, Germany). Electrospray
ionization–mass spectrometry, m/z: 386 (MH). Moreover, purity
of FTY720-P was measured by high-performance liquid chromato-
graphy. Therefore, synthesized FTY720-P or standard FTY720 was
dissolved in 275ml methanol/0.07M K2HPO4 (9:1). A derivatization
mixture of 10mg o-phthaldialdehyde, 200ml ethanol, 10ml
2-mercaptoethanol, and 10ml 3% boric acid was prepared and
adjusted to pH 10.5 with KOH. A 25ml portion of the derivatization
mixture was added to the resolved FTY720 (respectively, FTY720-P)
for 15minutes at room temperature. The derivatives were analyzed by
a Merck Hitachi LaChrom HPLC system (Merck Hitachi, Darmstadt,
Germany) using an RP 18 Kromasil column (Chromatographie Service,
Langerwehe, Germany). Separation was performed with a gradient of
methanol and 0.07M K2HPO4. Resulting profiles were evaluated using
the Merck system manager software, indicating no detectable amount
of FTY720 in the synthesized FTY720-P. FTY720-P was dissolved in
DMSO/HCl and for all cell culture experiments further diluted in
keratinocyte growth medium (KGM).
Keratinocyte culture
Human keratinocytes were isolated from juvenile foreskin by surgery
as described recently (Vogler et al., 2003). Briefly, skin was
incubated at 4 1C in a solution of 0.25% trypsin and 0.2% EDTA
for 20 hours. Trypsinization was terminated by addition of ice-cold
DMEM containing 10% fetal bovine serum. Keratinocytes were
separated from the epidermis by gently pivoting, washed with PBS,
and centrifuged at 250 g for 5minutes. After washing the cells with
PBS, the pellet was resuspended in KGM, which was prepared from
keratinocyte basal medium by the addition of 0.1 ngml1 epidermal
growth factor, 5.0 mgml1 insulin, 0.5 mgml1 hydrocortisone,
0.15mM Ca2þ , 30 mgml1 bovine pituitary extract, 50 mgml1
gentamycin sulfate, and 50 ngml1 amphotericin B. Keratinocytes
were pooled from several donors and cultured at 37 1C in 5% CO2.
For all cell experiments, keratinocytes were cultured for 24 hours in
KGM without insulin. The study was conducted according to the
Declaration of Helsinki Principles. An institutional approval for the
performed experiments was not necessary.
Quantitative real-time PCR
Keratinocytes were cultured in KGM, and RNA was collected using
an RNeasy kit (Qiagen, Foster City, CA). cDNA was generated from
total RNA using the FermentasAidTM First strand cDNA synthesis
kit (Fermentas GmbH, St Leon-Rot, Germany), according to the
instructions of the manufacturer. Quantitative real-time PCR was
performed using a LightCycler480 and the SYBR Green PCR master
mix (Roche Diagnostics–Applied Science, Mannheim, Germany).
CyclophilinA was used as a normalization control for all experi-
ments. For the measurement of the S1P receptor subtypes, the
following primers were used: S1P1: 5
0-CGTGTTCAGTCTCCTCG-30
(forward), 50-CTGATGCAGTTCCAGCC-30 (reverse); S1P2: 50-GTT
AGCCAGGATGGTCTT-30 (forward), 50-CAACAGAGCGAGACTT
CA-30 (reverse); S1P3: 50-CGCTTCAGTGTAAACAACG-30 (forward),
50-GAGGGTCACACAGCATT-30 (reverse); S1P4: 50-AAGACCAG
CCGCGTCTA-30 (forward), 50-CCAGGCAGAAGAGGATGT-30
(reverse); S1P5: 5
0-GGAAATGCAGCCAAAGG-30 (forward), 50-CCAT
TATTTCATCACCGAGTT-30 (reverse); cyclophilinA: 50-TTTGCTTAA
TTCTACACAGTACTTAGAT-30 (forward), 50-CTACCCTCAGGT
GGTCTT-30 (reverse). Total RNA (10 ng) of three different sets of
keratinocytes was used to analyze gene expression. Relative mRNA
expression was quantified using the comparative threshold cycle
method. Data were obtained in triplicate, and the specific mRNA
levels were expressed as the mean±SEM of relative mRNA
expression relative to control cells.
Western blot analysis
Keratinocytes were seeded in six-well plates and cultured for
24 hours in KGM without insulin. After stimulation, cells were
rinsed twice with ice-cold PBS and harvested in lysis buffer (PBS
without Ca2þ /Mg2þ , 1% Ipegal, 0.5% sodium desoxycholate, 0.1%
SDS, 1mM phenylmethylsulfonyl fluoride, 1 mgml1 leupeptin,
1mgml1 aprotinin, 1 mgml1 pepstatin, 1mM sodium orthovana-
date, and 50mM sodium fluoride). Lysates were centrifuged at
14,000 g for 30minutes. Samples containing 20–40 mg protein were
boiled in SDS sample buffer (100mM Tris/HCl (pH 6.8), 4% SDS,
0.2% bromophenol blue, 20% glycerol, 200mM dithiothreitol) and
separated by 10% SDS-PAGE. Gels were blotted overnight onto
polyvinylidene difluoride membranes. After blocking with 5% non-
fat dry milk for 1 hour at 37 1C, membranes were incubated with the
appropriate primary antibodies at a dilution of 1:1,000 for 2 hours at
room temperature, and further incubated with horseradish peroxi-
dase-conjugated secondary antibodies for 1 hour. Then blots were
developed according to the manufacturer’s protocol. Densitometry
measurements were recorded using a Syngene Gene Genius imaging
system (Syngene, Cambridge, UK). Values of the phosphorylated
proteins were normalized to the corresponding total protein level.
Deletion of S1P receptors using antisense technique
S1P1–5 receptor ASOs were designed to surround the translational
initiation site, a place empirically known to be most effective for
inhibition of gene expression. S1P receptor-specific ASOs were
synthesized based on the sequence of the mammalian S1P receptor
cDNAs. Same-length control oligonucleotides (with the same
nucleotides but randomly scrambled sequence) to the S1P receptor
subtypes were also designed: S1P1 ASO (5
0-GACGCTGG
TGGGCCCCAT-30) and S1P1 control oligonucleotides (50-ATGGGG
CCCACCAGCGTC-30); S1P2 ASO (50-GTTGAGCAGGGAATTCA
GGGTGGAGA-30) and S1P2 control oligonucleotides (50-CATCAC
TAGCCACTTGAAGCAGGCCA-30); S1P3 ASO (50-CGGGAGGGC
AGTTGCCAT-30) and S1P3 control oligonucleotides (50-ATGGC
AACTGCCCTCCCG-30); S1P4 ASO (50-GAAGGCCAGCAGGATCAT
CAGCAC-30) and S1P4 control oligonucleotides (50-ACCTAGCC
AACCCTCCATGAAGGC-30); S1P5 ASO (50-CAACATGCCAC
AAAGGCCAGGAG-30) and S1P5 control oligonucleotides (50-GCAA
CAACATAACGGGCCAGCA-30).
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For all antisense experiments, cells were treated with the
indicated ASO or control oligonucleotides for 2 days at a final
concentration of 500 nM using TransIT-LT1s in Optimem.
Abrogation of PKCd by siRNA
Downregulation of PKCd by siRNA (target sequence: 50-CCAUGAG
UUUAUCGCCACCTT-30) was performed according to the manu-
facturer’s protocol (Santa Cruz Biotechnology). Briefly, keratinocytes
were transfected with 50 nM of PKCd siRNA or control siRNA using
siRNA transfection reagent. Thereafter, siRNA and transfection
reagent were diluted in transfection medium and incubated at room
temperature for 30minutes. Cells were then incubated at 37 1C for
5 hours with the siRNA transfection complexes. After the transfection
period of 5 hours, the medium was changed to antibiotic-free KGM.
After a recovering time for 48 hours, proliferation and western blot
experiments were performed. The silencing efficiency was detected
by western blot analysis using anti-phospho-PKCd-antibody in
response to stimulation with TPA.
[3H]Thymidine incorporation assay
To determine DNA synthesis rates in cell culture experiments,
keratinocytes were grown in 24-well plates for 24 hours. Then
medium was replaced by fresh KGM without insulin and cells were
incubated with the indicated substances for 24 hours. After 20 hours,
cells were pulse labeled with 1 mCi [methyl-3H]thymidine per well
for 4 hours. The medium was removed and cells were washed twice
with PBS and ice-cold trichloroacetic acid (5%). The precipitated
material was dissolved in 0.3 N NaOH solution and incorporated
[methyl-3H]thymidine was determined in a scintillation counter
(MicroBeta Plus, Wallac Oy, Turku, Finland).
Statistical analysis
Data are expressed as the mean±SEM of results from at least three
experiments, each run in triplicate. Statistics were performed using
Student’s t-test. *Po0.05 and **Po0.01 indicate a statistically
significant difference versus control experiments.
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